Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent before any study procedures begin
• People aged between 20 and 75 years, of any gender
• People diagnosed with a specific type of oesophageal cancer called squamous cell carcinoma, confirmed by tissue biopsy and imaging, at a locally advanced stage involving certain lymph node or tumour spread patterns
• People whose cancer is located in the chest portion of the oesophagus
• People whose cancer cannot be surgically removed, either because of how the tumour has grown or because of lymph node involvement
• People who have a good general health and activity level, rated 0 or 1 on a standard medical scale (meaning able to carry out normal daily activities with little or no restriction)
• People whose estimated life expectancy is at least 6 months
• People who have not previously received any treatment for oesophageal cancer, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy
• People who have at least one tumour that can be measured using standard imaging criteria
• People whose organ function has been assessed and shows no reason to avoid surgery
• People with adequate organ function based on blood test results
• Women who could become pregnant must have a negative pregnancy test within 3 days before starting treatment; people of childbearing potential (male or female) must use highly effective contraception throughout the study and for either 120 days after the last dose of the study drug or 180 days after the last chemotherapy dose, whichever is longer

Who may not be able to join:

• People diagnosed with another cancer within the past 5 years (except for certain fully treated, non-invasive skin or cervical cancers, or early-stage lung lesions)
• People who currently have, or are at high risk of developing, an abnormal opening between the oesophagus and the windpipe or the aorta (major blood vessel)
• People whose cancer has spread to distant parts of the body
• People currently taking part in another interventional clinical trial, or who have received another experimental drug or device within the past 4 weeks
• People who have previously been treated with certain immunotherapy drugs that target specific immune system pathways (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapies)
• People who have received certain traditional Chinese medicine cancer treatments or immune-boosting drugs within the past 2 weeks
• People who have had an active autoimmune disease requiring ongoing systemic treatment within the past 2 years (excluding standard hormone replacement therapies)
• People who have taken systemic steroid medications or immune-suppressing drugs within the past 7 days, except at very low doses
• People who have had an organ transplant (other than a cornea transplant) or a bone marrow/stem cell transplant from another person
• People with a known allergy or sensitivity to the ingredients in the study drug
• People who have not yet adequately recovered from side effects of previous treatments (excluding tiredness or hair loss)
• People known to be living with HIV
• People with untreated, active hepatitis B infection above certain virus level thresholds (people with lower levels who are on antiviral medication may still be considered — confirm with trial site)
• People with active hepatitis C infection confirmed by blood tests
• People who have received a live vaccine within the past 30 days (certain inactivated flu vaccines may be acceptable — confirm with trial site)
• Women who are pregnant or breastfeeding
• People who have had gastrointestinal bleeding within the past 6 months, have a blood clotting disorder, or are currently taking blood-thinning or clot-dissolving medications with a high bleeding risk
• People with serious or uncontrolled health conditions, including significant heart rhythm problems, unstable chest pain or heart failure, a heart attack or stroke within the past 6 months, poorly controlled high blood pressure, lung inflammation requiring steroid treatment within the past year, active tuberculosis, active or uncontrolled infections, bowel blockage or abdominal abscess, significant liver disease, poorly controlled diabetes, significant protein in the urine, or mental health conditions that would affect the ability to follow the study requirements
• People with any other condition, history, or finding that the trial doctor believes would make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.